In animal models of AD, intranasal insulin was found to reduce cerebral oxidative stress, tau phosphorylation and amyloid load, and improves cognitive functions (Barone et al., 2019) (see Table 1). The gene discussed is MAPT; the disease is Alzheimer disease.